Can-Fite BioPharma (CANF) 6-K Principal Investigator Prof. Rifaat Safadi to present Namodenoson’s Phase II results at highly prestigious scientific conference for liver diseases

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

For the Month of September 2020

001-36203

(Commission File Number)

CAN-FITE BIOPHARMA LTD.

(Exact name of Registrant as specified in its charter)

10 Bareket Street

Kiryat Matalon, P.O. Box 7537

Petach-Tikva 4951778, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F  þ  Form 40-F  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

On September 30, 2020, Can-Fite BioPharma Ltd. (the “Company”) issued a press release announcing that the Scientific Program Committee of the American Association for the Study of Liver Diseases (AASLD) has selected the Company’s late-breaking abstract for oral presentation at The Liver Meeting Digital Experience™ 2020. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

1

Exhibit Index

Exhibit No.	Description
99.1	Press Release dated September 30, 2020

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: September 30, 2020	By:	/s/ Pnina Fishman
		Pnina Fishman
		Chief Executive Officer

3